July 3, 2025 07:23 AM EDT

Sage talked to 43 'counterparties' before inking Supernus deal

Kyle LaHucik

Biotech Correspondent

Sage Therapeutics talked with 43 “counterparties” over the course of last year and early 2025 as the 15-year-old company sought a lifeline for its grand …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

TRENDING NOW

Sage talked to 43 'counterparties' before inking Supernus deal

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

Now private, bluebird bio continues leadership revamp; Roche R&D exec announces retirement

Number of megarounds drop 38% in first half as biotechs struggle against worsening slump

4DMT lays off staff, reshuffles team as it doubles down on Phase 3 plans

Structure in partnering talks for GLP-1 pill as mid-stage readout nears

China’s rise splits US biotech investors: Cash in, or counter?

Dizal’s lung cancer pill approval sets up competition with J&J

Sage talked to 43 'coun­ter­par­ties' be­fore ink­ing Su­per­nus deal

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

more like this

Now pri­vate, blue­bird bio con­tin­ues lead­er­ship re­vamp; Roche R&D ex­ec an­nounces re­tire­ment

Num­ber of megarounds drop 38% in first half as biotechs strug­gle against wors­en­ing slump

4DMT lays off staff, reshuf­fles team as it dou­bles down on Phase 3 plans

Struc­ture in part­ner­ing talks for GLP-1 pill as mid-stage read­out nears

Chi­na’s rise splits US biotech in­vestors: Cash in, or counter?

Dizal’s lung can­cer pill ap­proval sets up com­pe­ti­tion with J&J

Sage talked to 43 'counterparties' before inking Supernus deal

Now private, bluebird bio continues leadership revamp; Roche R&D exec announces retirement

Number of megarounds drop 38% in first half as biotechs struggle against worsening slump

4DMT lays off staff, reshuffles team as it doubles down on Phase 3 plans

Structure in partnering talks for GLP-1 pill as mid-stage readout nears

China’s rise splits US biotech investors: Cash in, or counter?

Dizal’s lung cancer pill approval sets up competition with J&J